Fibre Extrusion Technology (FET) of Leeds, UK has delivered nine meltspinning systems to clients in the biomedical sector since the onset of the Covid-19 pandemic, with a similar number currently on order for 2021/22.
Fibre Extrusion Technology (FET) of Leeds, UK has delivered
nine meltspinning systems to clients in the biomedical sector since the onset
of the Covid-19 pandemic, with a similar number currently on order for 2021/22.
FETâ€™s position as an acknowledged world leader in meltspinning equipment for
the production of precursor materials used in medical devices and the default
supplier for absorbable suture production systems, with orders virtually
doubling year on year.
Slack, Managing Director, FET said that, FET has a long tradition in the highly
regulated biomedical sector and they believe that their experience is
unrivalled. They have built a world leading reputation for melt spinning
medical grade polymers in both synthetic resorbable and non-absorbable polymers
and FET is now reaping the rewards of this initiative.
installations include a multi-functional system that can produce both
multifilament and monofilament pre-cursor fibres, but nonwoven systems have
been particularly prominent, driven by the burgeoning demand for FFP3 masks,
gowns and other medical products required during the pandemic. Research
organisations have also invested in FET systems for biomedical applications.
The FET in-house Process Development Laboratory
and ongoing collaboration with biomaterial polymer suppliers has helped to
optimise the biomedical melt spinning technology. This Laboratory is at the
disposal of customers for all aspects of confidential testing and evaluation.
To further increase this competitive edge, FET will be opening a new Process
Development Laboratory and Visitor Centre in early 2022.
Image Source: FET Press
Source: FET Press Release